ABSTRACT
Introduction Danon disease (DD) is a rare X-linked dominant cardioskeletal myopathy caused by mutations in the lysosome-associated membrane protein-2 gene. Though the severe morbidity of disease in males is well established, longitudinal studies describing the trajectory of cardiovascular disease in both sexes have not been performed. Herein we performed an analysis using the International Danon Disease Registry, a retrospective dataset that includes longitudinal data from a cohort of males and females with DD.
Methods Data were from the International Danon Disease Registry and includes patients from 2005 to 2022. Records were obtained from the first episode of care to the date of enrollment and included demographics, clinical characteristics, echocardiographic and laboratory values, and outcomes. The primary outcome in this study was a heart failure (HF) composite defined as either transplant (TXP), left ventricular assist device (LVAD) or death.
Results The analysis included 116 DD patients: female (n=64, 55%) and male (n=52, 45%). Median age of diagnosis for the entire cohort was 15.2 years (10.0-25.2 years), and 21.9 years (15.0-34.9 years) and 12.4 years (7.1-15.6 years) for females and males respectively. The incidence of HF outcome was higher in males compared to females (p<0.001). Regarding trends in echocardiographic parameters over time, LVEF decreased and LVEDD increased regardless of sex and HF outcome, however, rate of change was increased in patients who experienced a HF outcome in both sexes. Increasing LV mass occurs in males but not females. Consistent with this, LV wall hypertrophy continues in males who have not yet experienced a HF outcome and stabilizes prior to HF outcome, while females have progressive LV thinning regardless of HF outcome. Analyses stratified by age of HF outcome in females found two distinct groups of females, one who experienced HF outcome prior to 26 years of age and another after.
Conclusions In this largest longitudinal natural history study of DD to date, we confirmed that males present on average a decade earlier and demonstrate more progressive cardiac hypertrophy and heart failure than females. Of note, there may be a subset of females who are phenotypically similar to males with profound LV hypertrophy that appears to stabilize or regress prior to HF outcome. Correlations between structural changes including LV hypertrophy, dilation and dysfunction and disease progression may allow for risk stratification of Danon patients and refinement of treatment algorithms while also informing therapeutic trial design.
Competing Interest Statement
AA and QBI report consulting fees from Lexeo Therapeutics. JS and ST are employees and shareholders of Rocket Pharmaceuticals. EDA serves as Chief Medical Officer and Head of Research for Lexeo Therapeutics, is a shareholder of Rocket Pharmaceuticals, Founder of Papillion Therapeutics, and Founder, Scientific board member, and shareholder of Corstasis Therapeutics. MT serves as principal investigator on a research grant from Rocket Pharmaceuticals. The remaining authors have nothing to disclose.
Clinical Trial
NCT03766386, NCT05548855, NCT06214507
Funding Statement
This work was funded by Grant MDA 67944. AA and QBI report consulting fees from Lexeo Therapeutics. JS and ST are employees and shareholders of Rocket Pharmaceuticals. EDA serves as Chief Medical Officer and Head of Research for Lexeo Therapeutics, is a shareholder of Rocket Pharmaceuticals, Founder of Papillion Therapeutics, and Founder, Scientific board member, and shareholder of Corstasis Therapeutics. MT serves as principal investigator on a research grant from Rocket Pharmaceuticals. The remaining authors have nothing to disclose.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRBs used were University of California, San Diego local IRB and University of Colorado, Denver local IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Not Applicable
Data Availability
All data is available from International Danon Disease Registry.
